OncoMatch/Clinical Trials/NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Is NCT04613596 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments for advanced non-small cell lung cancer.
Treatment: Adagrasib · Adagrasib · Adagrasib · Adagrasib · Pembrolizumab — The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C
KRAS G12C mutation
Required: PD-L1 (CD274) any tested (any PD-L1 TPS)
any PD-L1 TPS
Required: PD-L1 (CD274) any tested (PD-L1 TPS >=50%)
PD-L1 TPS >=50%
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: systemic therapy
Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 007-556-A · Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley · Prescott Valley, Arizona
- Local Institution - 007-568-A · Safford, Arizona
- Local Institution - 007-568-B · Safford, Arizona
- Local Institution - 007-568-C · Safford, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04613596 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require KRAS?
Yes, KRAS G12C is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify